Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,379.34 116.78 0.72%
S&P 500 1,856.52 13.54 0.73%
NASDAQ 4,066.21 32.05 0.79%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip,



   Preliminary Financial Results, Quarterly Reports and Upcoming Conference
Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine,
                                 and Antares

PR Newswire

NEW YORK, November 11, 2013

NEW YORK, November 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Avanir
Pharmaceuticals, Inc. (NASDAQ: AVNR), BioScrip, Inc. (NASDAQ: BIOS), Chemed
Corporation (NYSE: CHE), Foundation Medicine, Inc. (NASDAQ: FMI), and Antares
Pharma, Inc. (NASDAQ: ATRS). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Avanir Pharmaceuticals, Inc. Research Report

On October 29, 2013, Avanir Pharmaceuticals, Inc. (Avanir) reported
preliminary financial information for full-year FY 2013 (period ended
September 30, 2013). Based on the preliminary financial information reported
by the Company, total gross revenues for full-year FY 2013 are estimated to be
nearly $95.9 million, while net revenues are estimated to be between $75.3
million to $76.3 million. "We are delighted with the progress of our NUEDEXTA
PBA commercial business this year," said Keith Katkin, President and CEO of
Avanir. "In addition, the R&D team has made great progress with our pipeline.
We now have three active phase II studies of AVP-923 including MS neuropathic
pain, Alzheimer's agitation, and the recently announced levodopa-induced
dyskinesias in Parkinson's disease. We continue to expect top-line data from
our PRIME study in MS neuropathic pain later this calendar year." The Full
Research Report on Avanir Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/2ee8_AVNR]

--

BioScrip, Inc. Research Report

On November 6, 2013, BioScrip, Inc. (BioScrip) reported its Q3 2013 financial
results. During the quarter, the Company's revenue increased 22.6% YoY to
$208.9 million. Q3 2013 net loss from continuing operations was $22.4 million,
or $0.35 per diluted share, compared with a net loss of $0.6 million or $0.01
per diluted share, in Q3 2012. "Our core infusion business continued to
deliver strong margins and double-digit organic revenue growth in the third
quarter," said Rick Smith, President and CEO of BioScrip. "We closed the
CarePoint acquisition during the quarter and our acquisitions are on track to
achieve their targeted range of 12 to 14 percent long-term EBITDA margins,
once fully integrated. These underlying results demonstrate our success in
implementing our plan to deliver growth across a national infusion footprint."
The Full Research Report on BioScrip, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/4879_BIOS]

--

Chemed Corporation Research Report

On November 6, 2013, Chemed Corporation (Chemed) announced that it will make a
presentation at the 2013 Credit Suisse Healthcare Conference. The Company
informed that the presentation will take place on November 12, 2013 at
approximately 8:00 a.m. MT at the Phoenician Hotel in Scottsdale, AZ. The
presentation will be webcast live and can be accessed through the Chemed
website. The Full Research Report on Chemed Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4c0d_CHE]

--

Foundation Medicine, Inc. Research Report

On November 6, 2013, Foundation Medicine, Inc. (Foundation Medicine) reported
its Q3 2013 financial results. During the quarter, the Company's revenues
totaled $8.2 million, up 170.3% YoY. The Company informed that more than half
of its quarterly revenues came from clinical testing. Q3 2013 net loss was
$12.5 million, or $3.51 loss per basic and diluted share, compared with a net
loss of $5.6 million, or $2.39 per basic and diluted share, in Q3 2012.
"Results in the third quarter demonstrate the growing enthusiasm in the
marketplace for our fully informative genomic profile for use across all solid
tumors," said Michael Pellini, M.D., President and CEO of Foundation Medicine.
"We are very encouraged by the commercial traction as the utility of
FoundationOne and the information it delivers garners growing recognition
among oncologists, pathologists and pharmaceutical companies. In addition, the
number of scientific publications generated using our molecular information
platform during the quarter continues to underscore its clinical utility and
value in the care of patients with cancer." The Full Research Report on
Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d9a0_FMI]

--

Antares Pharma, Inc. Research Report

On November 6, 2013, Antares Pharma, Inc. (Antares) reported its Q3 2013
financial results. The Company's revenues totaled $5.5 million, down 3.1% YoY
during the quarter. Q3 2013 net loss was $0.05 per basic and diluted share,
compared with a net loss of $0.03 per basic and diluted share, in Q3 2012.
"Last month's approval of OTREXUP represented a strategic milestone in the
transformation of Antares from a royalty based business to a specialty
pharmaceutical company generating potential product revenue from proprietary
in-house development programs," said Paul K. Wotton, Ph.D., President and CEO
of Antares. "We believe that OTREXUP could become an important part of the
treatment continuum for RA patients and look forward to launching the product
early in 2014." The Full Research Report on Antares Pharma, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2353_ATRS]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com

 

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement